An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

A novel avian influenza subtype, A/H7N9, emerged in 2013 and represents a public health threat with pandemic potential. We have previously shown that DNA vaccine priming increases the magnitude and quality of antibody responses to H5N1 monovalent inactivated boost. We now report the safety and immun...

Descripción completa

Detalles Bibliográficos
Autores principales: DeZure, Adam D., Coates, Emily E., Hu, Zonghui, Yamshchikov, Galina V., Zephir, Kathryn L., Enama, Mary E., Plummer, Sarah H., Gordon, Ingelise J., Kaltovich, Florence, Andrews, Sarah, McDermott, Adrian, Crank, Michelle C., Koup, Richard A, Schwartz, Richard M., Bailer, Robert T., Sun, Xiangjie, Mascola, John R., Tumpey, Terrence M., Graham, Barney S., Ledgerwood, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627236/
https://www.ncbi.nlm.nih.gov/pubmed/29263871
http://dx.doi.org/10.1038/s41541-017-0016-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627236/
https://www.ncbi.nlm.nih.gov/pubmed/29263871
http://dx.doi.org/10.1038/s41541-017-0016-6

Ejemplares similares